Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 178 entries
View as:

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT01349660 Org: User:
Start: 12/31/11 End: 12/29/18 Due: 12/29/19

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

Phase: N/A Priority: Normal
NCT ID: NCT02436772 Org: User:
Start: 05/13/15 End: 07/07/17 Due: 07/07/18

SCRI Tissue Testing Registry

Phase: N/A Priority: Normal
NCT ID: NCT00965861 Org: User:
Start: 05/31/10 End: 02/28/13 Due: 02/28/14

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193271 Org: User:
Start: 08/31/04 End: 05/31/07 Due: 05/31/08

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00193544 Org: User:
Start: 03/31/02 End: 01/31/09 Due: 01/31/10

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00402883 Org: User:
Start: 11/30/06 End: 01/31/09 Due: 01/31/10

iCORE: Collaborative Orthopedics Outcomes Registry

Phase: N/A Priority: Normal
NCT ID: NCT02422667 Org: User:
Start: 04/30/15 End: 04/30/17 Due: 04/30/18

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00632489 Org: User:
Start: 05/31/08 End: 07/31/11 Due: 07/31/12

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT02195011 Org: User:
Start: 07/31/14 End: 06/04/17 Due: 06/04/18

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00731211 Org: User:
Start: 09/30/08 End: 09/30/12 Due: 09/30/13

Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00906282 Org: User:
Start: 06/30/09 End: 09/30/15 Due: 09/30/16

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00741988 Org: User:
Start: 09/30/08 End: 09/30/12 Due: 09/30/13

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00193518 Org: User:
Start: 04/30/04 End: 04/30/06 Due: 04/30/07

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01056276 Org: User:
Start: 05/31/10 End: 02/28/17 Due: 02/28/18

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT02035124 Org: User:
Start: 04/30/14 End: 01/31/15 Due: 01/31/16

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00544817 Org: User:
Start: 04/30/07 End: 08/31/10 Due: 08/31/11

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT01028313 Org: User:
Start: - End: - Due: -

Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193141 Org: User:
Start: 10/31/99 End: 07/31/07 Due: 07/31/08

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Phase: N/A Priority: Normal
NCT ID: NCT00360360 Org: User:
Start: 07/31/06 End: 03/31/09 Due: 03/31/10

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00308529 Org: User:
Start: 03/31/06 End: 01/31/09 Due: 01/31/10

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Phase: N/A Priority: Normal
NCT ID: NCT00193609 Org: User:
Start: 09/30/04 End: 01/31/09 Due: 01/31/10

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT01042288 Org: User:
Start: 06/30/10 End: 07/31/15 Due: 07/31/16

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01014351 Org: User:
Start: 02/28/10 End: 08/31/13 Due: 08/31/14

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Phase: N/A Priority: Normal
NCT ID: NCT01990209 Org: User:
Start: 03/31/14 End: 05/01/21 Due: 05/01/22

Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01844817 Org: User:
Start: 09/30/13 End: 03/31/16 Due: 03/31/17